Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022827 | 1.00 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2BHTR2B | |
| SCHEMBL3026932 | 0.90 | ADORA3 (0.59) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL3026443 | 0.89 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BHTR2B | |
| SCHEMBL10158773 | 0.86 | ADORA3 (0.56) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL27792071 | 0.83 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL3016051 | 0.83 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156707 | 0.83 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| Hydrochloric Acid SCHEMBL3024763 | 0.82 | ADORA3 (0.65) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156799 | 0.82 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL10156671 | 0.82 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2205601-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050199-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA1 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.